Abstract:Background Cirrhosis, the end result of liver injury, has high mortality globally. The effect of country-level income on mortality from cirrhosis is unclear. We aimed to assess predictors of death in inpatients with cirrhosis using a global consortium focusing on cirrhosis-related and access-related variables. Methods In this prospective observational cohort study, the CLEARED Consortium followed up inpatients with cirrhosis at 90 tertiary care hospitals in 25 countries across six continents. Consecutive patients older than 18 years who were admitted non-electively, without COVID-19 or advanced hepatocellular carcinoma, were enrolled. We ensured equitable participation by limiting enrolment to a maximum of 50 patients per site. Data were collected from patients and their medical records, and included demographic characteristics; country; disease severity (MELD- Na score); cirrhosis cause; medications used; reasons for admission; transplantation listing; cirrhosisrelated history in the past 6 months; and clinical course and management while hospitalised and for 30 days post discharge. Primary outcomes were death and receipt of liver transplant during index hospitalisation or within 30 days post discharge. Sites were surveyed regarding availability of and access to diagnostic and treatment services. Outcomes were compared by country income level of participating sites, defined according to World Bank income classifications (high-income countries [HICs], upper-middle-income countries [UMICs], and low-income or lower-middle-income countries [LICs or LMICs]). Multivariable models controlling for demographic variables, disease cause, and disease severity were used to analyse the odds of each outcome associated with variables of interest. Findings Patients were recruited between Nov 5, 2021, and Aug 31, 2022. Complete inpatient data were obtained for 3884 patients (mean age 55 center dot 9 years [SD 13 center dot 3]; 2493 (64 center dot 2%) men and 1391 (35 center dot 8%) women; 1413 [36 center dot 4%] from HICs, 1757 [45 center dot 2%] from UMICs, and 714 [18 center dot 4%] from LICs or LMICs), with 410 lost to follow-up within 30 days after hospital discharge. The number of patients who died while hospitalised was 110 (7 center dot 8%) of 1413 in HICs, 182 (10 center dot 4%) of 1757 in UMICs, and 158 (22 center dot 1%) of 714 in LICs and LMICs (p<0 center dot 0001), and within 30 days post discharge these values were 179 (14 center dot 4%) of 1244 in HICs, 267 (17 center dot 2%) of 1556 in UMICs, and 204 (30 center dot 3%) of 674 in LICs and LMICs (p<0 center dot 0001). Compared with patients from HICs, increased risk of death during hospitalisation was found for patients from UMICs (adjusted odds ratio [aOR] 2 center dot 14 [95% CI 1 center dot 61-2 center dot 84]) and from LICs or LMICs (2 center dot 54 [1 center dot 82-3 center dot 54]), in addition to increased risk of death within 30 days post discharge (1 center dot 95 [1 center dot 44-2 center dot 65] in UMICs and 1 center dot 84 [1 center dot 24-2 center dot 72] in LICs or LMICs). Receipt of a liver transplant was recorded in 59 (4 center dot 2%) of 1413 patients from HICs, 28 (1 center dot 6%) of 1757 from UMICs (aOR 0 center dot 41 [95% CI 0 center dot 24-0 center dot 69] vs HICs), and 14 (2 center dot 0%) of 714 from LICs and LMICs (0 center dot 21 [0 center dot 10-0 center dot 41] vs HICs) during index hospitalisation (p<0 center dot 0001), and in 105 (9 center dot 2%) of 1137 patients from HICs, 55 (4 center dot 0%) of 1372 from UMICs (0 center dot 58 [0 center dot 39-0 center dot 85] vs HICs), and 16 (3 center dot 1%) of 509 from LICs or LMICs (0 center dot 21 [0 center dot 11-0 center dot 40] vs HICs) by 30 days post discharge (p<0 center dot 0001). Site survey results showed that access to important medications (rifaximin, albumin, and terlipressin) and interventions (emergency endoscopy, liver transplantation, intensive care, and palliative care) varied geographically. Interpretation Inpatients with cirrhosis in LICs, LMICs, or UMICs have significantly higher mortality than inpatients in HICs independent of medical risk factors, and this might be due to disparities in access to essential diagnostic and treatment services. These results should encourage researchers and policy makers to consider access to services and medications when evaluating cirrhosis-related outcomes.

Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, west Africa: a prospective cohort study

Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub‐Saharan Africa: Systematic review and meta‐analysis

Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)–Coinfected Patients With High HBV Replication

Sociodemographic and medical characteristics of liver cirrhosis deaths in a Ghanaian tertiary hospital

Hepatocellular carcinoma surveillance among people living with hepatitis B in Senegal (SEN-B): insights from a prospective cohort study

Chronic hepatitis B virus infection in Eastern Ethiopia: Clinical characteristics and determinants of cirrhosis

Challenges of Hepatitis B Treatment in Rural Sub‐Saharan Africa: Treatment Initiation and Outcomes from a Public Hospital‐Based Clinic in Kono, Sierra Leone

Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial)

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP).

Risk factors, clinical characteristics, and treatment outcomes for hepatocellular carcinoma in Rwanda.

Epidemiology of hepatitis B virus and/or hepatitis C virus infections among people living with human immunodeficiency virus in Africa: A systematic review and meta-analysis.

Characteristics and antiviral treatment eligibility of newly diagnosed hepatitis B patients at a teaching hospital in Ghana: Implications for prevention and management

Characteristics and antiviral treatment eligibility of patients diagnosed with hepatitis B at a teaching hospital in Ghana: Implications for prevention and management

Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a reconstructed individual patient data meta-analysis

Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa

Managing cirrhosis with limited resources: perspectives from sub-Saharan Africa

Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study

Hepatitis B Virus-Induced Cirrhosis: Mechanisms, Global Variations, and Treatment Advances

cfDNA and associated risk factors in the early diagnosis of cancers in Côte d’Ivoire: The case of primary liver cancer related to viral hepatitis B

Global Disparities in Mortality and Liver Transplantation in Hospitalised Patients with Cirrhosis: a Prospective Cohort Study for the CLEARED Consortium

Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir—A Propensity Score–Matched Study